Non-Alcoholic Fatty Liver Disease: Pathophysiology, Diagnosis, and Emerging Therapies
Fuente:
Zenodo
Salvato in:
| Autore principale: | |
|---|---|
| Natura: | Recurso digital |
| Pubblicazione: |
Zenodo
2025
|
| Soggetti: | |
| Accesso online: | |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!
|
| _version_ | 1866902266711113728 |
|---|---|
| author | Amit Namde*, Amey Dhuri, Nutan Gaikwad, Rini Punathil, Dr. Kamlesh Soni |
| author_facet | Amit Namde*, Amey Dhuri, Nutan Gaikwad, Rini Punathil, Dr. Kamlesh Soni |
| contents | <p><span lang="EN-US">Non-alcoholic fatty liver disease (NAFLD) has emerged as the most common chronic liver disorder worldwide, affecting nearly one-fourth of the global population. It encompasses a spectrum ranging from simple steatosis to non-alcoholic steatohepatitis (NASH), progressive fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). NAFLD is strongly linked with obesity, insulin resistance, type 2 diabetes mellitus, and dyslipidaemia, making it a hepatic manifestation of metabolic syndrome. The disease pathogenesis involves excessive hepatic lipid accumulation driven by increased fatty acid uptake, de novo lipogenesis, impaired fatty acid oxidation, and defective lipid export, ultimately leading to lipo-toxicity, oxidative stress, inflammation, and fibrosis. Diagnosis traditionally relies on liver biopsy, but non-invasive biomarkers and imaging modalities are increasingly employed. Lifestyle modification through diet and exercise remains the cornerstone of management, while pharmacological options such as pioglitazone and vitamin E are recommended in selected patients. Emerging therapies, including FXR agonists (obeticholic acid), PPAR ligands (elafibranor), and GLP-1 receptor agonists (liraglutide, semaglutide, resmetirom), hold promise for disease modification. Despite advances, no FDA-approved drug is yet available, highlighting the urgent need for effective therapies. This review summarises the molecular mechanisms, diagnostic strategies, current management, and future therapeutic perspectives in NAFLD.</span></p> |
| format | Recurso digital |
| id | zenodo_https___doi_org_10_5281_zenodo_17313048 |
| institution | Zenodo |
| language | |
| publishDate | 2025 |
| publisher | Zenodo |
| record_format | zenodo |
| spellingShingle | Non-Alcoholic Fatty Liver Disease: Pathophysiology, Diagnosis, and Emerging Therapies Amit Namde*, Amey Dhuri, Nutan Gaikwad, Rini Punathil, Dr. Kamlesh Soni Non-alcoholic fatty liver disease, NASH, Lipotoxicity, Insulin resistance, FXR agonists, GLP-1 receptor agonists, Metabolic syndrome. <p><span lang="EN-US">Non-alcoholic fatty liver disease (NAFLD) has emerged as the most common chronic liver disorder worldwide, affecting nearly one-fourth of the global population. It encompasses a spectrum ranging from simple steatosis to non-alcoholic steatohepatitis (NASH), progressive fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). NAFLD is strongly linked with obesity, insulin resistance, type 2 diabetes mellitus, and dyslipidaemia, making it a hepatic manifestation of metabolic syndrome. The disease pathogenesis involves excessive hepatic lipid accumulation driven by increased fatty acid uptake, de novo lipogenesis, impaired fatty acid oxidation, and defective lipid export, ultimately leading to lipo-toxicity, oxidative stress, inflammation, and fibrosis. Diagnosis traditionally relies on liver biopsy, but non-invasive biomarkers and imaging modalities are increasingly employed. Lifestyle modification through diet and exercise remains the cornerstone of management, while pharmacological options such as pioglitazone and vitamin E are recommended in selected patients. Emerging therapies, including FXR agonists (obeticholic acid), PPAR ligands (elafibranor), and GLP-1 receptor agonists (liraglutide, semaglutide, resmetirom), hold promise for disease modification. Despite advances, no FDA-approved drug is yet available, highlighting the urgent need for effective therapies. This review summarises the molecular mechanisms, diagnostic strategies, current management, and future therapeutic perspectives in NAFLD.</span></p> |
| title | Non-Alcoholic Fatty Liver Disease: Pathophysiology, Diagnosis, and Emerging Therapies |
| topic | Non-alcoholic fatty liver disease, NASH, Lipotoxicity, Insulin resistance, FXR agonists, GLP-1 receptor agonists, Metabolic syndrome. |
| url | https://doi.org/10.5281/zenodo.17313048 |